Back to top
more

TG Therapeutics (TGTX)

(Delayed Data from NSDQ)

$25.25 USD

25.25
4,270,764

+0.17 (0.68%)

Updated Sep 18, 2024 04:00 PM ET

Pre-Market: $25.89 +0.64 (2.53%) 8:01 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 26% (65 out of 251)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for TGTX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

1 item in cart

View Cart/Checkout

TG Therapeutics, Inc. [TGTX]

Reports for Purchase

Showing records 1 - 20 ( 278 total )

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 1

08/06/2024

Company Report

Pages: 6

2Q24 Results; Strong Briumvi Sales; Full Year Guidance Raised Again

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 2

05/02/2024

Company Report

Pages: 7

1Q24 Results; Strong Briumvi Sales Beat Expectations; Raising PT to $49

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 3

04/18/2024

Daily Note

Pages: 3

National Contract With the Department of Veterans Affairs For Briumvi as Preferred Anti-CD20 for RMS

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 4

03/01/2024

Daily Note

Pages: 3

Phase 3b ENHANCE Study Data Presented at ACTRIMS

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 5

02/28/2024

Company Report

Pages: 7

4Q23 Results; 2024 Guidance Unchanged; Exceptional Briumvi Sales Growth Expected in 2024

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 6

02/26/2024

Company Report

Pages: 7

International Partner, Neuraxpharm, Launches Briumvi in Germany, Triggering $12.5M Milestone Payment

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 7

01/11/2024

Company Report

Pages: 7

Preliminary 4Q23 and FY23 U.S. Briuvmi Sales Ahead of Estimates; Raising 2024 Revenue Estimate and Price Target

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 8

01/09/2024

Daily Note

Pages: 4

Global License Agreement With Precision BioSciences For Precision''s Allogeneic CD19 CAR T Program in Autoimmune Diseases

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 9

11/22/2023

Company Report

Pages: 6

Optimized Entry and Exit Levels for TGTX 112223

Provider: Stock Traders Daily

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 10

11/02/2023

Company Report

Pages: 6

3Q23 Results; Briumvi Sales Exceed Expectations

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 11

10/11/2023

Daily Note

Pages: 3

Positive Data Update For Briumvi at ECTRIMS

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 5.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 12

09/18/2023

Company Report

Pages: 6

Highlights From Fireside Chat With TG Therapeutics

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 13

08/01/2023

Company Report

Pages: 6

2Q23 Results; Briumvi OUS Marketing Deal Announced; U.S. Sales Double Sequentially and Beat Our Estimate

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 14

06/01/2023

Daily Note

Pages: 3

Briumvi Receives Approval From the European Commission For the Treatment of Adults With RMS

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 5.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 15

05/31/2023

Daily Note

Pages: 3

Data From ULTIMATE I and II Trials to be Presented at the 2023 Consortium of Multiple Sclerosis Centers Annual Meeting

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 5.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 16

05/01/2023

Company Report

Pages: 6

1Q23 Results; Initial Briumvi Sales Exceed Expectations; Raising PT by $6

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 17

04/27/2023

Daily Note

Pages: 3

J-Code Issuance For Briumvi Announced

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 5.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 18

04/14/2023

Company Report

Pages: 7

Model Update; Raising Price Target

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 19

03/31/2023

Daily Note

Pages: 3

Positive CHMP Opinion For Briumvi For the Treatment of Relapsing Forms of Multiple Sclerosis

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 5.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 20

03/03/2023

Daily Note

Pages: 3

Planned ULTIMATE I & II Data Presentations Announced For the American Academy of Neurology (AAN) Annual Meeting

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 5.00

Research Provided by a Third Party
// eof